PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL

• Shenmiao Yang,
• Haiwen Huang,
• Keshu Zhou,
• Xielan Zhao,
• Yan-Qiu Han#,
• Lindong LI,
• Anna Butturini,
• Yiqiu Wang,
• Xiaofeng Liu,
• Peiqiong Lai,
• Jianyong LI

Affiliations

Shenmiao Yang

1 Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing, China

Haiwen Huang

2 The First Hospital of Soochow University, Suzhou

Keshu Zhou

3 Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China

Xielan Zhao

4 Xiangya Hospital Central South University, Xiangya, China

Yan-Qiu Han#

5 The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China

Lindong LI

6 AstraZeneca, Shanghai, China

Anna Butturini

7 AstraZeneca, South San Francisco, United States

Yiqiu Wang

6 AstraZeneca, Shanghai, China

Xiaofeng Liu

6 AstraZeneca, Shanghai, China

Peiqiong Lai

6 AstraZeneca, Shanghai, China

Jianyong LI

8 The First Affiliated Hospital With Nanjing Medical University, Nanjing, China